BIIB•benzinga•
Biogen Begins Phase 3 Study Of Felzartamab For The Treatment Of Late Antibody-Mediated Rejection (AMR) In Kidney Transplant Patients
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 11, 2025 by benzinga